Drug intelligence / Profile preview

S-1 + erlotinib

Development stage: Discontinued
Lead developer: Astellas Pharma
Modality: Small Molecules
Administration: Oral

Overview

S-1 + erlotinib is a combination therapy consisting of S-1, an oral fluoropyrimidine anticancer agent, and erlotinib, an EGFR tyrosine kinase inhibitor. This combination was studied in a Phase I/II clinical trial for previously treated non-small cell lung cancer (NSCLC). In this study, the treatment regimen involved erlotinib 150 mg/body orally once daily and S-1 orally on days 1-14 every three weeks. The recommended dose was determined to be erlotinib 150 mg/body and S-1 80 mg/m².

Targets

EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on S-1 + erlotinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S-1 + erlotinib.

Explore the full profile